These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 30376864)
1. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864 [TBL] [Abstract][Full Text] [Related]
2. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout. Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091 [No Abstract] [Full Text] [Related]
3. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink. Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034 [TBL] [Abstract][Full Text] [Related]
5. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout. Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929 [TBL] [Abstract][Full Text] [Related]
6. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study. Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661 [TBL] [Abstract][Full Text] [Related]
7. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. Levy G; Shi JM; Cheetham TC; Rashid N Perm J; 2018; 22():17-142. PubMed ID: 30201087 [TBL] [Abstract][Full Text] [Related]
8. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Juraschek SP; Kovell LC; Miller ER; Gelber AC Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123 [TBL] [Abstract][Full Text] [Related]
10. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England. Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461 [TBL] [Abstract][Full Text] [Related]
11. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting. Lee S; So MW Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782 [TBL] [Abstract][Full Text] [Related]
12. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research. Feng X; Li Y; Gao W Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042 [TBL] [Abstract][Full Text] [Related]
13. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805 [TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy. Sultan AA; Muller S; Whittle R; Roddy E; Mallen C; Clarson L CMAJ; 2019 Jun; 191(22):E597-E603. PubMed ID: 31160496 [TBL] [Abstract][Full Text] [Related]
15. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194 [TBL] [Abstract][Full Text] [Related]
16. Cohort study investigating gout flares and management in UK general practice. Finnikin S; Mallen CD; Roddy E BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770 [TBL] [Abstract][Full Text] [Related]
17. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. Levy GD; Rashid N; Niu F; Cheetham TC J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523 [TBL] [Abstract][Full Text] [Related]
18. Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397 [TBL] [Abstract][Full Text] [Related]
19. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. Singh JA; Cleveland JD BMC Nephrol; 2019 Mar; 20(1):93. PubMed ID: 30876398 [TBL] [Abstract][Full Text] [Related]
20. Cardiac and renal protective effects of urate-lowering therapy. Richette P; Latourte A; Bardin T Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i47-i50. PubMed ID: 29272510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]